PortfoliosLab logoPortfoliosLab logo
MDLN vs. JNJ
Performance
Return for Risk
Dividends
Drawdowns
Volatility
Financials

Performance

MDLN vs. JNJ - Performance Comparison

The chart below illustrates the hypothetical performance of a $10,000 investment in Medline Inc (MDLN) and Johnson & Johnson (JNJ). The values are adjusted to include any dividend payments, if applicable.

Loading graphics...

MDLN vs. JNJ - Yearly Performance Comparison


2026 (YTD)2025
MDLN
Medline Inc
4.76%2.44%
JNJ
Johnson & Johnson
18.59%-1.61%

Fundamentals

Market Cap

MDLN:

$35.73B

JNJ:

$595.41B

EPS

MDLN:

$1.45

JNJ:

$11.04

PE Ratio

MDLN:

30.25

JNJ:

22.12

PEG Ratio

MDLN:

0.15

JNJ:

0.74

PS Ratio

MDLN:

1.23

JNJ:

6.29

PB Ratio

MDLN:

3.33

JNJ:

7.30

Total Revenue (TTM)

MDLN:

$28.43B

JNJ:

$94.19B

Gross Profit (TTM)

MDLN:

$6.99B

JNJ:

$68.56B

EBITDA (TTM)

MDLN:

$3.11B

JNJ:

$39.85B

Returns By Period

In the year-to-date period, MDLN achieves a 4.76% return, which is significantly lower than JNJ's 18.59% return.


MDLN

1D
-1.12%
1M
-4.03%
YTD
4.76%
6M
1Y
3Y*
5Y*
10Y*

JNJ

1D
-0.13%
1M
-1.79%
YTD
18.59%
6M
32.75%
1Y
63.73%
3Y*
19.86%
5Y*
11.54%
10Y*
11.40%
*Multi-year figures are annualized to reflect compound growth (CAGR)

Compare stocks, funds, or ETFs

Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.


Return for Risk

MDLN vs. JNJ — Risk / Return Rank

Compare risk-adjusted metric ranks to identify better-performing investments over the past 12 months.

MDLN

JNJ
JNJ Risk / Return Rank: 9797
Overall Rank
JNJ Sharpe Ratio Rank: 9898
Sharpe Ratio Rank
JNJ Sortino Ratio Rank: 9898
Sortino Ratio Rank
JNJ Omega Ratio Rank: 9898
Omega Ratio Rank
JNJ Calmar Ratio Rank: 9595
Calmar Ratio Rank
JNJ Martin Ratio Rank: 9797
Martin Ratio Rank
The rank (0–100) shows how this investment's returns compare to the risk taken. Higher = better. Based on the past 12 months of data, combining Sharpe, Sortino, and other metrics used by quantitative funds and institutional investors.

MDLN vs. JNJ - Risk-Adjusted Trends Comparison

This table presents a comparison of risk-adjusted performance metrics for Medline Inc (MDLN) and Johnson & Johnson (JNJ). Risk-adjusted metrics are performance indicators that assess an investment's returns in relation to its risk, enabling a more accurate comparison of different investment options.


Risk / return metrics aren't available yet — we need at least 12 months of trading data to calculate them.

MDLN vs. JNJ - Sharpe Ratio Comparison


Loading graphics...

Sharpe Ratios by Period


MDLNJNJDifference

Sharpe Ratio (1Y)

Calculated over the trailing 1-year period

3.67

Sharpe Ratio (5Y)

Calculated over the trailing 5-year period

0.70

Sharpe Ratio (10Y)

Calculated over the trailing 10-year period

0.62

Sharpe Ratio (All Time)

Calculated using the full available price history

0.70

0.54

+0.16

Correlation

The correlation between MDLN and JNJ is 0.16, which is considered to be low. This implies their price changes are not closely related. A low correlation is generally favorable for portfolio diversification, as it helps to reduce overall risk by spreading it across multiple assets with different performance patterns.


Dividends

MDLN vs. JNJ - Dividend Comparison

MDLN has not paid dividends to shareholders, while JNJ's dividend yield for the trailing twelve months is around 2.13%.


TTM20252024202320222021202020192018201720162015
MDLN
Medline Inc
0.00%0.00%0.00%0.00%0.00%0.00%0.00%0.00%0.00%0.00%0.00%0.00%
JNJ
Johnson & Johnson
2.13%2.48%3.40%3.00%2.52%2.45%2.53%2.57%2.74%2.38%2.73%2.87%

Drawdowns

MDLN vs. JNJ - Drawdown Comparison

The maximum MDLN drawdown since its inception was -17.84%, smaller than the maximum JNJ drawdown of -50.67%. Use the drawdown chart below to compare losses from any high point for MDLN and JNJ.


Loading graphics...

Drawdown Indicators


MDLNJNJDifference

Max Drawdown

Largest peak-to-trough decline

-17.84%

-50.67%

+32.83%

Max Drawdown (1Y)

Largest decline over 1 year

-8.42%

Max Drawdown (5Y)

Largest decline over 5 years

-18.41%

Max Drawdown (10Y)

Largest decline over 10 years

-27.37%

Current Drawdown

Current decline from peak

-11.98%

-1.79%

-10.19%

Average Drawdown

Average peak-to-trough decline

-6.72%

-11.89%

+5.17%

Ulcer Index

Depth and duration of drawdowns from previous peaks

2.51%

Volatility

MDLN vs. JNJ - Volatility Comparison


Loading graphics...

Volatility by Period


MDLNJNJDifference

Volatility (1M)

Calculated over the trailing 1-month period

4.43%

Volatility (6M)

Calculated over the trailing 6-month period

10.94%

Volatility (1Y)

Calculated over the trailing 1-year period

40.87%

19.11%

+21.76%

Volatility (5Y)

Calculated over the trailing 5-year period, annualized

40.87%

16.67%

+24.20%

Volatility (10Y)

Calculated over the trailing 10-year period, annualized

40.87%

18.33%

+22.54%

Financials

MDLN vs. JNJ - Financials Comparison

This section allows you to compare key financial metrics between Medline Inc and Johnson & Johnson. You can select fields from income statements, balance sheets, and cash flow statements to easily visualize and compare the financial health of both companies.


Quarterly
Annual

Total Revenue: Total amount of money received from sales and other business activities


10.00B15.00B20.00B25.00BJulyOctober2022AprilJulyOctober2023AprilJulyOctober2024AprilJulyOctober2025AprilJulyOctober
7.79B
24.56B
(MDLN) Total Revenue
(JNJ) Total Revenue
Values in USD except per share items

MDLN vs. JNJ - Profitability Comparison

The chart below illustrates the profitability comparison between Medline Inc and Johnson & Johnson over time, highlighting three key metrics: Gross Profit Margin, Operating Margin, and Net Profit Margin.

Gross Margin
Operating Margin
Net Margin
Quarterly
Annual

20.0%30.0%40.0%50.0%60.0%70.0%80.0%90.0%JulyOctober2022AprilJulyOctober2023AprilJulyOctober2024AprilJulyOctober2025AprilJulyOctober
24.6%
86.4%
Portfolio components
MDLN - Gross Margin

Gross margin is calculated as gross profit divided by revenue. For the three months ending on Apr 2026, Medline Inc reported a gross profit of 1.91B and revenue of 7.79B. Therefore, the gross margin over that period was 24.6%.

JNJ - Gross Margin

Gross margin is calculated as gross profit divided by revenue. For the three months ending on Apr 2026, Johnson & Johnson reported a gross profit of 21.22B and revenue of 24.56B. Therefore, the gross margin over that period was 86.4%.

MDLN - Operating Margin

Operating margin is calculated as operating income divided by revenue. For the three months ending on Apr 2026, Medline Inc reported an operating income of 425.00M and revenue of 7.79B, resulting in an operating margin of 5.5%.

JNJ - Operating Margin

Operating margin is calculated as operating income divided by revenue. For the three months ending on Apr 2026, Johnson & Johnson reported an operating income of 5.39B and revenue of 24.56B, resulting in an operating margin of 22.0%.

MDLN - Net Margin

Net margin is calculated as net income divided by revenue. For the three months ending on Apr 2026, Medline Inc reported a net income of 180.00M and revenue of 7.79B, resulting in a net margin of 2.3%.

JNJ - Net Margin

Net margin is calculated as net income divided by revenue. For the three months ending on Apr 2026, Johnson & Johnson reported a net income of 5.12B and revenue of 24.56B, resulting in a net margin of 20.8%.